Salsalate as an Adjunctive Treatment for Patients With Schizophrenia
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This is a 12-week, open-label trial of salsalate 3 g/day as an adjunctive treatment in 15
schizophrenia subjects to examine salsalate's effect on psychopathology, cognitive
functioning, and metabolic parameters.
Potential subjects will be identified by their clinicians at the Freedom Trail Clinic, or
Massachusetts General Hospital. A total of 15 subjects will be enrolled.